Roivant Sciences is expanding its scope to the lungs, unveiling a new subsidiary whose main asset, licensed from Bayer, offers the potential to bring patients a novel treatment for a rare type of ...

Interstitial lung disease (ILD) refers to a group of conditions that cause damage and stiffness in the lung tissue. Over time, this damage can make it harder for oxygen to move into the bloodstream.

Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments ...

The target of AllRock Bio’s research is already validated by FDA-approved medicines — for the eyes. The biotech startup is expanding that science to the lungs with a drug candidate licensed from ...

GOTHENBURG, Sweden, Feb. 4, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ...

PAH therapies improved hemodynamic parameters and reduced NT-proBNP levels in PH-ILD patients, indicating potential benefits. Precision medicine could help identify PH-ILD patients who may benefit ...

Dr. Sathish Kumar Krishnan has spent years tackling a silent crisis in healthcare: pulmonary hypertension (PH), a condition that affects thousands but remains underdiagnosed and under-treated. As a ...